Browse > Article
http://dx.doi.org/10.14456/apjcp.2016.183/APJCP.2016.17.8.3861

Lack of Association between Serum Adiponectin/Leptin Levels and Medullary Thyroid Cancer  

Abooshahab, Raziyeh (Department of Biology, Faculty of Basic Sciences, Science Research Campus of Islamic Azad University)
Yaghmaei, Parichehr (Department of Biology, Faculty of Basic Sciences, Science Research Campus of Islamic Azad University)
Ghadaksaz, Hoda Gholab (Cellular and Molecular Research Centre, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences)
Hedayati, Mehdi (Cellular and Molecular Research Centre, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.8, 2016 , pp. 3861-3864 More about this Journal
Abstract
Background: Adipokines are bioactive proteins that mediate metabolism, inflammation and angiogenesis. Changes in the secretion of key serum adipokines - adiponectin and letpin - may be associated with obesity, cancer and metabolic disorders. Thyroid cancer is one of the most important types of endocrine cancer. Therefore, investigating the association between serum levels of adiponectin and leptin and thyroid cancer might be important. The purpose of this study was to assess adiponectin and leptin levels in medullary thyroid carcinoma (MTC) cases in order to identify novel tumor markers. Materials and Methods: This research was based on a case-control study, including 45 patients with medullary thyroid cancer (21 men and 24 women) and 45 healthy controls (24 males and 21 females). Adiponectin and leptin levels were measured by ELISA in both groups. Height and weight were measured and body mass index (kg/m2) was calculated. Results: Adiponectin and leptin levels were not significantly different between medullary thyroid carcinomas and the control group. Also, there was no correlation among age and body mass index and the disease. Conclusions: These results suggest that changes in serum adiponectin and leptin levels do not play an important role in the diagnosis or could act as as biomarkers for medullary thyroid cancer.
Keywords
Adiponectin; leptin; medullary thyroid carcinoma; body mass index;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ahima R, Flier J (2000). Adipose tissue as an endocrine organ. Trends Endocrinol Metabolism, 11, 327-32.   DOI
2 Ahima R (2006). Adipose tissue as an endocrine organ. Obesity, 14, 242-9.   DOI
3 Akinci M, Kosova F, Cetin B, et al (2009). Leptin levels in thyroid cancer. Asian J Surg, 32, 216-23.   DOI
4 Liang J, Zubovitz J, Petrocelli T, et al (2002). PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature Med, 8, 1153-60.   DOI
5 Mandal P, Pratt B, Barnes M, et al (2011). Molecular mechanism for Adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. J Biological Chem, 286, 13460-9.   DOI
6 Mitsiades N, Pazaitou-Panayiotou K, Aronis K, et al (2011). Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metabolism, 96, 2023-8.   DOI
7 Otvos L, Haspinger E, La Russa F, et al (2011). Design and development of a peptide-based adiponectin receptor agonist for cancer treatment. BMC Biotechnol, 11, 90.   DOI
8 Paz-Filho G (2011). Associations between adipokines and obesity-related cancer. Frontiers Bioscience, 16, 1634.   DOI
9 Park J, Euhus D, Scherer P (2011). Paracrine and Endocrine Effects of Adipose Tissue on Cancer Development and Progression. Endocrine Rev, 32, 550-70.   DOI
10 Peso L (1997). Interleukin-3-induced phosphorylation of BAD through the Protein Kinase Akt. Science, 278, 687-9.   DOI
11 Berg A, Combs T, Scherer P (2002). ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends in Endocrinol Metabolism, 13, 84-9.   DOI
12 Banks A (2000). Activation of downstream signals by the long form of the leptin receptor. J Biological Chemistry, 275, 14563-72.   DOI
13 Barb D, Williams C, Neuwirth A, Mantzoros C (2007). Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr, 86, 858-66.   DOI
14 Baratta M (2002). Leptin-from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit, 8, 282-92.
15 Booth A, Magnuson A, Fouts J, Foster M (2015). Adipose tissue, obesity and adipokines: role in cancer promotion. Hormone Molecular Biol Clin Investigat.
16 Danese E, Minicozzi AM, Montagnana M, et al (2013). Lack of an Association between circulating adiponectin levels and risk of colorectal adenoma. Clinical Laboratory.
17 Pezzilli R, Barassi A, Corsi M, et al (2010) Serum leptin, but not adiponectin and receptor for advanced glycation end products, is able to distinguish autoimmune pancreatitis from both chronic pancreatitis and pancreatic neoplasms. Scandinavian J Gastroenterol, 45, 93-9.   DOI
18 Pontikides N, Krassas G (2007). Basic endocrine products of adipose tissue in states of thyroid dysfunction. Thyroid, 17, 421-31.   DOI
19 Segev D, Umbricht C, Zeiger M (2003). Molecular pathogenesis of thyroid cancer. Surgical Oncol, 12, 69-90.   DOI
20 Cheng S, Chi C, Tzen C, et al (2010). Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery, 147, 847-53.   DOI
21 Di Cristofano A (2013). Obesity and thyroid cancer: Is Leptin the (Only) Link? Endocrinol, 154, 2567-9.   DOI
22 Fruhbeck G (2006). Intracellular signalling pathways activated by leptin. Biochem J, 393, 7-20.   DOI
23 Griebeler M, Gharib H, Thompson G (2013). Medullary thyroid carcinoma. Endocrine Practice, 19, 703-11.   DOI
24 Hedayati M, Yeganeh M, Sheikholeslami S, Azizi F (2015). Wide screening of RET proto-oncogene in Iranian medullary thyroid carcinoma patients: 13 years study. Endocrine Abstracts.
25 Stevens V, Jacobs E, Sun J, Gapstur S (2014). No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev, 23, 890-2.   DOI
26 Tworoger S, Eliassen A, Kelesidis T, et al (2007). Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metabolism, 92, 1510-6.   DOI
27 Uddin S, Bu R, Ahmed M, et al (2010). Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. Leukemia Lymphoma, 51, 1305-14   DOI
28 Hedayati M, Zarif Yeganeh M, Sheikhol Eslami S, et al (2011). Predominant RET germline mutations in exons 10, 11, and 16 in iranian patients with hereditary medullary thyroid carcinoma. J Thyroid Res, 2011, 1-6.
29 Hedayati M, Nabipour I, Rezaei-Ghaleh N, Azizi F (2006). Germline RET mutations in exons 10 and 11: an Iranian survey of 57 medullary thyroid carcinoma cases. Med J Malaysia, 61, 564-9.
30 Hedayati M, Yaghmaei P, Pooyamanesh Z, et al (2011). Leptin: A Correlated Peptide to Papillary Thyroid Carcinoma? J Thyroid Res, 2011, 1-5.
31 Bub J, Miyazaki T, Iwamoto Y (2006). Adiponectin as a growth inhibitor in prostate cancer. Biophys Res Commun, 340, 1158-66.   DOI
32 Howard J, Pidgeon G, Reynolds J (2010). Leptin and gastrointestinal malignancies. Obesity Rev, 11, 863-74.   DOI
33 Kim A, Lee Y, Kim K, et al(2010). Adiponectin Represses Colon Cancer Cell Proliferation via AdipoR1- and -R2-Mediated AMPK Activation. Molecular Endocrinol, 24, 1441-52.   DOI
34 Kadowaki T, Yamauchi T (2005). Adiponectin and Adiponectin Receptors. Endocrine Rev, 26, 439-51.   DOI
35 Kaklamani V, Wisinski K, Sadim M, et al (2008). Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA, 300, 1523-31   DOI